Thou Shalt Get Busy? Religious Leaders Ask Congregants to Have More Sex

By Sally Chew

Istockphoto/Health
When Fellowship Church Rev. Ed Young last month called for members of his evangelical mega-church to have seven days of sex, he said it was to foster intimacy and faithfulness. But I wondered what else the quirky young pastor might turn up—on purpose or not—with his new headline-grabbing campaign.

Having frequent sex is believed to help ward off prostate cancer, heart problems, depression depression, and even outward signs of aging. So even if just a core group of Fellowship’s 20,000 members manage to double their rates of “congregational copulation”—as Young suggested—they might reap some physical benefits too. Read More

Hormone Therapy Only Helps Some Older Men With Prostate Cancer

(HealthDay News) -- Adding hormone therapy to radiation treatment for fast-moving prostate cancer can save lives, but the benefit often doesn't apply to men who have other serious medical problems, a new study shows.

"The new message from this study is that there definitely is a difference in outcome, depending on the gentleman's health," said Dr. Anthony V. D'Amico, chief of genitourinary oncology at Brigham and Women's Hospital in Boston. His report is published in the Jan. 23 issue of the Journal of the American Medical Association.

The old message, reported in 2004 on the five-year point of the study, was that treatment to suppress the activity of male hormones known as androgens improved survival of older men with aggressive prostate cancer, D'Amico said.

But the new report showed the benefit was limited to men without other serious medical problems. Adding hormone therapy to radiation treatment in the 206-man study decreased the rate of death significantly, but the benefit was confined to men without other health issues.

"This report is important, because it is part of a story that is emerging about hormone therapy in men with prostate cancer who are elderly," D'Amico said. "If a man is 75 and otherwise healthy, adding hormone therapy is likely to help. If the same man has had a heart attack or stroke, or if he is a smoker or diabetic, adding hormone therapy makes it worse."

In terms of clinical practice, the finding means that "before I treat him, I get him to a specialist and try to get his health cleared up as much as possible before giving the hormone therapy," D'Amico said. "If he has heart disease, I would consult a cardiologist; if a stroke, I would consult a neurologist; if diabetes, a diabetologist."

The idea is not anything new in medicine, he added. "It is the same as with a surgical procedure," D'Amico said. "You do not give the therapy until it is cleared by the appropriate specialist."

The study is relatively small and requires further confirmation, said Dr. Durado Brooks, director of prostate and colorectal cancer at the American Cancer Society.

"But for men trying to make a decision about prostate cancer treatment, it provides useful information for the men and their physicians," Brooks said. "A man who has had radiation treatment, if he and his doctor talk about the results of this study, it can help them make a decision about hormone treatment in a more informed way."

The results apply to "a significant percentage of older prostate cancer patients," Brooks said, noting that the average age of men in the study was over 70.

Until now, only general advice about hormone treatment could be given to such men, he said. "Now we can be a little more specific and say, 'If you don't have underlying cardiac disease or other major co-morbid conditions, the chance of having a good response to the treatment is better.' But many men with heart disease or other problems may decide they do not want to deal with the side effects of hormone treatment."

More information
Learn more about prostate cancer and its treatment from the American Cancer Society.

Oxy-Powder® Complete Cleansing System $147.75 [ learn more ] Complete Cleansing System with Livatrex™, Oxy-Powder®, Latero-Flora™, and two bottles of ParaTrex®.

Breast Cancer Genes Also Raise Men's Risk for Malignancy

(HealthDay News) -- Men whose mothers, sisters or daughters test positive for a breast cancer-causing mutation in the BRCA1 or BRCA2 genes may also have the mutation and be at increased risk for cancer, a new study finds.

Most of those men are unaware of the danger, noted researchers at Fox Chase Cancer Center in Philadelphia, who examined how families discuss genetic test results.

Men with a mutation in the BRCA1 or BRCA2 genes have a 14 percent lifetime risk of developing prostate cancer and a 6 percent lifetime risk of developing breast cancer, the study authors said.

"Despite these health implications, we have found a lack of understanding of genetic test results among men in these families," study lead author Dr Mary B. Daly, senior vice president for population science at Fox Chase, said in a prepared statement.

The researchers interviewed 24 men with a first-degree female relative who tested positive for a BRCA1 or BRAC2 mutation. All the women said they told their male relative about the test results, but only 18 of the men remembered that they were told.

About half the men (7) who did remember being told the test results didn't believe that they also had an increased risk of cancer. Only 5 of the men correctly assessed their chance of having a BRCA1 or BRCA 2 mutation.

"We devote a significant amount of time learning how best to communicate genetic test results to women, but this study shows we also need to help them communicate the information to their male family members who may be impacted by the test results," Daly concluded.

The study was expected to be presented Friday at the San Antonio Breast Cancer Symposium.

More information
The U.S. National Cancer Institute has more about cancer genetics.

Prostate Cancer Survival Varies by Season

(HealthDay News) -- Men diagnosed with prostate cancer in the summer and fall have a better chance of survival than those diagnosed in the spring and winter, a new study of Norwegian men suggests.

"Summer and autumn months correspond to times when vitamin D is highest (in Norway).

Although the study does not prove vitamin D is the determining factor, it does suggest that this possibility should be studied further," study co-author Dr. Tomasz Beer, director of the prostate cancer program at the Oregon Health & Science University Cancer Institute, said in a prepared statement.

In the study, a team of American and Norwegian researchers analyzed data for more than 46,000 Norwegian men diagnosed with prostate cancer from 1964 to 1992.

Compared with men diagnosed in the summer and fall, those diagnosed in the winter and spring were 20 percent more likely to die within three years after diagnosis. The study was published in the journal The Prostate.

The researchers also examined whether survivability was affected by factors such as eating foods high in vitamin D (such as fatty fish), taking vacations in sunny southern locations, and where the men lived in Norway.

Only age seemed to have a influence -- younger men had a slightly better rate of survival. The researchers noted that the capacity of skin to produce vitamin D when exposed to sunshine is about 40 percent lower in men 75 and older than in men 60 and younger.

Vitamin D, which has been shown to inhibit cancer growth, may also help maintain immune system health and help regulate cell growth and differentiation, Beer said.

More information
The American Cancer Society has more about prostate cancer.

Most Asian Men Have Better Prostate Cancer Survival Rates

(HealthDay News) -- Your prognosis for surviving prostate cancer may depend on your racial and ethnic background, a new study suggests.

Asian men have better survival rates than white males, while South Asians have the worst survival rates, according to results of a study of men living in California.

"Nearly all Asians do far better when they get prostate cancer," said study lead author Dr. Anthony Robbins, of the California Cancer Registry in Sacramento. "But Indian men didn't do as well as other Asian men, and they did worse than all other men, including blacks and whites," he added.

The reasons for these racial and ethnic differences in prostate cancer survival aren't known, Robbins said, adding, "We just couldn't explain it."

Not only couldn't the researchers explain the finding, they were left with an apparent paradox. The Asian men were usually older and had more advanced disease at the time of diagnosis, Robbins said. "Based on their risk factors, you would think they were going to do worse," he said.

In the study, Robbins and his colleagues collected data on 116,916 men (108,076 whites and 8,840 Asians from the six largest represented Asian ethnicities -- Chinese, Filipino, Japanese, Korean, South Asian, and Vietnamese) diagnosed with prostate cancer. The researchers compared prognostic factors and survival rates among the men.

The researchers found that for Asians, risk profiles were worse compared with whites. For example, Asians were more likely to have more advanced disease and use non-curative therapies. But, for Asians -- except for South Asians -- survival rates were equal to or better than rates for whites.

Japanese-American men were 34 percent less likely to die from prostate cancer compared with whites. But South Asian men -- those from India, Pakistan, Bangladesh, Sri Lanka, Nepal, and Bhutan -- were 40 percent more likely to die from the disease, Robbins said.

The study was published online Monday in the journal Cancer.

Some of the factors that may influence the findings include diet, exercise and genetics, Robbins speculated.

"Doctors that are seeing patients for prostate cancer need to be aware that these differences can be used as factors in planning the patient's treatment and telling the patient what their survival might be," Robbins said.

Dr. Durado Brooks, director of prostate and colorectal cancer at the American Cancer Society, thinks this study demonstrates the need to better understand how different racial and ethnic groups respond to diseases.

"This study points out the potential misleading conclusions we can come to when we use these large groups to lump different subpopulations into," he said.

"If you lump in the South Asian subgroup with other Asians, as is traditionally done, you totally miss the fact that these folks have a strikingly higher chance of dying from prostate cancer," Brooks said.

Brooks said the study finding can provide a basis for research to try to understand why these differences exist between populations.

Prostate cancer is the most common type of cancer to strike American men, other than skin cancer, according to the American Cancer Society, which estimates there will be about 218,890 new cases of prostate cancer in the United States in 2007, and about 27,050 men will die of the disease. Prostate cancer is the second leading cause of cancer death in males. While one in six men will get prostate cancer during his lifetime, only one man in 34 will die of the disease. The death rate for prostate cancer is declining, due in large part to earlier diagnoses, the society said.

Another paper in the same issue of the journal also found racial differences among women who survive breast cancer; with black women having poorer survival regardless of the stage of the disease.

It is known that black women had larger tumors and are more likely to have invasive breast cancer. But the study, lead by Dr. Alfred Neugut from Columbia University Medical Center and Russell McBride from Mailman School of Public Health, found that mortality among black women was up to 56 percent higher than whites.

Neugut's team says that the disparities in survival were surprising and suggest that non-clinical factors, such as access to and quality of care, may play a part.

More information
For more on prostate cancer, visit the American Cancer Society.

Health Tip: Risk Factors for Prostate Cancer

(HealthDay News) -- Prostate cancer is one of the most common cancers that affect men. While most cases aren't fatal, it is important to understand the risk factors for the disease to help recognize symptoms and begin treatment early.

The U.S. National Cancer Institute lists these potential risk factors for prostate cancer:

Aging.
High levels of testosterone.
A high-fat diet, which may increase the risk. (A low-fat diet rich in fruits and vegetables may help the risk.)
Blacks are at much greater risk of prostate cancer, whites are at intermediate risk, and Japanese have the lowest average risk.

High-Tech Radiation Boosts Prostate Cancer Survival

(HealthDay News) -- Most prostate cancer patients treated with high-dose, intensity modulated radiation therapy (IMRT) were still alive and cancer-free an average of eight years after treatment, according to a large new study.

The study -- the first to describe long-term outcomes for prostate cancer patients treated with IMRT -- was conducted by a team from Memorial Sloan-Kettering Cancer Center in New York City and is published in the October issue of the Journal of Urology.

Before treatment, researchers divided 561 patients into three groups based on their cancer prognosis: favorable, intermediate and unfavorable.

An average of eight years after IMRT, 89 percent of men in the favorable group were still alive, along with 78 percent of those in the intermediate group, and 67 percent of those in the unfavorable group.

Of the men who were potent before IMRT, nearly half (49 percent) developed erectile dysfunction.

IMRT is an improved form of what's known as "three-dimensional conformal radiation therapy." It uses enhanced planning-treatment software that more precisely targets the prostate. This allows the beam of radiation to deliver a high dose to the tumor, while sparing the nearby bladder and rectum from being exposed to these higher amounts of radiation.

"Our results suggest that IMRT should be the treatment of choice for delivering high-dose, external beam radiotherapy for patients with localized prostate cancer," Dr. Michael J. Zelefsky, chief of the brachytherapy service at Memorial Sloan-Kettering, said in a prepared statement.

"This study confirms that we can improve patients' quality of life by reducing the side effects of radiotherapy, while maintaining disease-free survival," he said. "However, there is still room for improvement. We are incorporating image-guided approaches that may continue the excellent tumor control but further limit the area we are irradiating and reduce side effects."

More information
The American Academy of Family Physicians has more about prostate cancer treatments.

more information abour the products:
http://www.kamarani.com/index.htm?aff=dreddyclinic

Holocaust Survivors at Higher Long-Term Cancer Risk

(HealthDay News) -- A new study finds that rates of cancer and cancer-related death are especially high among survivors of the Holocaust in Israel.

An Israeli research team found that Holocaust survivors who emigrated from Europe to Israel following World War II are at higher risk for cancer compared to European Jews who moved there before the war began.

Much of the difference can be attributed to cancers found among the youngest Holocaust survivors. Specifically, male and female immigrants born in Europe between 1940 and 1945 faced the highest odds of developing breast or colorectal cancers, the researchers found.
While the findings may have implications for survivors of mass atrocities in general, they are of immediate concern to the 238,600 Holocaust survivors still living in Israel, said study co-author Dr. Micha Barchana.

"The bad news is that Holocaust survivors are at a higher risk to get cancer, but the good news is that we can do something [about it]," he said. "We are focusing on the practical implementation of the research results: the need for survivors to participate in early-detection programs that are offered in Israel as well as in most modern countries, due to the finding that classifies them as a high-risk population," he explained.

Barchana serves as the director of the National Cancer Registry in the Israeli Health Ministry and is also a senior lecturer in the school of public health at the University of Haifa in Israel.
He and his colleagues presented their research earlier this year at the International Agency for Research on Cancer, held in Lyon, France.

The work was funded by the Israel Cancer Society.
Barchana's team reviewed records from the Israeli government's Central Bureau of Statistics to first draft a list of all Jewish immigrants to Israel born in Europe between 1920 and 1945.
They then turned to the Israeli Health Ministry's National Cancer Registry to compile cancer incidence and death rates among these immigrants.

The researchers found that those immigrants born between 1920 and 1945 who came to Israel between the end World War II and 1989 were at significantly higher risk for cancer than immigrants born between 1920 and 1939 who migrated to Israel before the onset of World War II.

Barchana said his team does not know how many of the post-war European immigrants suffered through the experience of Nazi concentration camps or wartime Jewish ghettos. However, he said his team assumed that many or most did, and that, in any case, "all the Jews in Europe at war time had gone through severe food deprivation and other stresses."

Higher cancer risks seemed to linger for decades for this group, the researchers found. Male Holocaust survivors experienced a 14 percent higher cancer incidence rate than pre-war immigrants and were 2.4 times more likely to get cancer than their pre-war compatriots.

Female Holocaust survivors had a 21 percent higher rate of cancer than pre-war immigrants and were 2.3 times more likely to have a cancer diagnosis than pre-war immigrants.

Breaking down cancer incidence by specific diseases, the authors found that Holocaust survivors were at a significantly higher risk for lung cancer, Kaposi's sarcoma (a rare form of skin malignancy), and prostate cancer.

Heightened risks for certain other cancers stood out. For example, male Holocaust survivors were nine times more likely to be diagnosed with cancer of the large intestine than pre-war immigrants. Female Holocaust survivors faced more than double the risk for cancer of the large intestine and a 50 percent higher risk of developing breast cancer, the study found.

In addition, Barchana's team found that the younger the Holocaust survivor was during the war, the greater their risk for getting cancer. In fact, most of the increase in risk among Holocaust survivors was borne by those who were 14 years of age or younger during World War II.

Barchana said that finding has been shown in other studies involving survivors of terrible events. "Research on A-bomb survivors in Japan clearly shows that women that were at a young age are at higher risk of developing cancer later in life," he said. Similar data is emerging among those affected by the Chernobyl nuclear plant accident, Barchana added.

Patients who had survived the Holocaust also had a tougher battle to fight off the disease once it was diagnosed, the researchers found. According to Barchana, that may be due to the fact that "Holocaust survivors are being diagnosed at later stages compared to the control group."

Five-year cancer survival rates were 5 percent to 13 percent lower among Holocaust survivors compared to other immigrants, regardless of sex or age.

According to the researchers, the findings suggest that severe deprivation, from whatever cause, may weaken the body's long-term defenses against cancer. Inmates in the Nazi concentration camps suffered prolonged exposure to extreme poverty, food deprivation, over-crowding, harsh weather, physical abuse and mental stress.

The authors called for Holocaust survivors and their families to be increasingly vigilant about cancer detection, particularly for breast and colorectal cancers, and to avail themselves of the free screenings for such diseases that are currently available in Israel.

On a wider note, Barchana emphasized the role that food deprivation probably plays as a contributing factor to increased cancer risk.

"There has been some (prior) data on the possible role of malnutrition in breast cancer etiology," he remarked. "This work completes this knowledge, and this aspect of the study should be further investigated," Barchana said.

Dr. Michael Thun, vice president of epidemiology and surveillance research with the American Cancer Society in Atlanta, said the study was interesting and, in some ways, surprising.

"When one compares these results to studies of the Dutch Famine of 1944 to 1945, what they had found was that there was an increase in breast cancer risk, but they did not find the same increase in other cancers," Thun noted. "So, in this study, it was surprising to me that there was an increase in risk in colorectal cancer and a range of different cancers," he said.

"But in the case of the Holocaust, people had so many terrible things happen that it's even more complex and dreadful than just the famine resulting from war," added Thun. "So, I agree with the authors' conclusions that closer screening of these people is warranted to detect cancers early," he said.

More information
For advice on cancer screening, visit the American Cancer Society.

Sunlight May Help You Survive Cancer

SUNBATHING could improve your chances of surviving cancer, doctors say.
Those diagnosed with the disease in summer and autumn live longer than those diagnosed at other times of the year, British research shows.

This is probably because their vitamin D levels are topped up by sun exposure.
Researchers say vitamin D can affect the rate of cell division in tumour development and can trigger the self- destruction of cells developing in the wrong way.

The study of more than one million patients suggests the season when cancer is detected and treated could make a significant difference to progress of the disease.

It says that diagnosis in the summer and autumn months is 'associated with improved survival, especially in lung and breast cancer patients.

'We found sunlight exposure to be a predictor of cancer survival.

'Our results add to a growing body of evidence that vitamin D may play an important role in cancer survival.' The study, which is a fast track publication in the International Journal of Cancer, looked at 590,000 men and 606,000 women diagnosed between 1971 and 2002. Diagnoses made in summer and autumn when blood levels of vitamin D are highest had the lowest risk of death.

Women with breast cancer had a 14 per cent lower risk of death, while women with bowel cancer were 6 per cent less likely to die.

There was a reduction of 6 per cent in the death rate for all cancers combined for both sexes when diagnosed in summer and autumn.

The study, which was led by Dr Henrik Moller, head of the Thames Cancer Registry based at King's College London, analyzed their season of diagnosis, with summer and autumn defined as June 1 to November 30.

The researchers also obtained data on sunlight from the British Meteorological Office and calculated levels of cumulative sunlight hours for each season during the study period.
Their report says the results support the hypothesis that variation in vitamin D levels through sunlight exposure lies behind the differences in survival.

But it says data on sunlight hours probably underestimates the true effect of exposure because it does not measure the intensity of light which is much stronger in summer and would have a more significant impact on blood levels of vitamin D.

The findings come as evidence grows that vitamin D could play a vital role in helping prevent disease, with sun exposure helping to top up natural levels more effectively than through diet.
A study last year showed taking a large dose of vitamin D every day 1,000 international units (IU) or 25mcg could halve your chance of developing cancers such as breast, ovarian, colon, and prostate.

Oliver Gillie, who runs Health Research Forum, a not-for-profit organisation, published a report showing that topping up levels of vitamin D could help prevent more than 25 chronic diseases.
He added: 'The research evidence shows Government advice to avoid sunbathing is misguided.
Tanning should properly be seen as a sign of health, as indeed it is by most members of the public, although care should be taken to avoid burning.'

Mr Gillie said cancer patients should get advice from their doctors about whether they can safely sunbathe, as chemotherapy and radiotherapy can sensitize the skin to sunlight.
Date: July 5, 2006

© 2006 Daily Mail. via ProQuest Information and Learning Company;
All Rights Reserved

Puzzled by Prostate Test Scores?

Puzzled by Prostate Test Scores?
Provided by: DrWeil.com

Q: What do you make of the new study showing that the test for prostate cancer may miss some disease? How can men best protect themselves? -- Robert P.

A: Results of a study published in the May 27, 2004, issue of the New England Journal of Medicine showed that the blood test for prostate cancer misses about 15 percent of all cases, some of which are aggressive enough to be life-threatening. The test looks for a protein (prostate specific antigen, known as PSA) released by prostate cells when cancer is present and as the prostate enlarges, which it does as men age. Until results of the study were published, a PSA count under four meant that a man was disease-free; the higher the PSA count, the more likely the presence of cancer. The only reliable way to currently confirm or rule out cancer is with a biopsy.

Now that the study has found that some men with a PSA of "four" or lower may still have cancer, doctors don't know what to recommend. To be safe, some specialists say they'll suggest biopsies to all men with a PSA above 2.5; others think there already are too many biopsies, too much testing and needless treatment of prostate cancers that might never become life-threatening. While prostate cancer can be very aggressive, most tumors grow slowly and the risk of death is low -- only three percent. What we need is a better test to distinguish between slow growing tumors that may not require treatment and fast-growing cancer that demands an aggressive approach.

Several methods have been suggested to improve the testing methods for prostate cancer and thus reduce the number of unnecessary biopsies. Adjusting the expected results for the age of the patient and size of the prostate as well as measuring PSA changes over time are some possibilities.

Still, decisions on how to best handle early prostate cancer will remain clouded until better tests are developed and perfected.

In the meantime, make sure that you and your doctor are aware of your personal risks. The incidence of prostate cancer increases with age; the disease occurs most frequently among African-American men, those with a family history of the disease, and those whose diets are high in animal fat.

To reduce your risk, include more watermelon, pink grapefruit, and cooked tomatoes in your diet. All contain the prostate protective antioxidant lycopene. I also recommend drinking lots of water (dehydration stresses the prostate), adding soy foods to your diet and eating less fat, particularly saturated fats found in red meat as well as hydrogenated oils, processed foods and other sources of trans fats. (Be sure to eat the right kinds of fat such as olive oil, avocados and nuts.)
Andrew Weil, MD

An Antioxidant Update?

An Antioxidant Update?
Provided by: DrWeil.com

Q: I just bought some supplements and the clerk at the health food store told me I needed to take 6,000 mg of vitamin C per day. That sounds like an awful lot. What do you recommend? -- Barbara B.

A: I used to recommend taking 2,000 to 6,000 mg of vitamin C daily (divided into three doses). However, I changed my recommendation in 1999 to 200 mg daily after examining two well-designed studies showing that lower levels of vitamin C more than saturate the body's tissues, and thus are sufficient to protect against cancer, heart disease and other chronic illnesses.
One of the studies that influenced my decision was a review of clinical trials published in the April 21, 1999, issue of the Journal of the American Medical Association.

It concluded that 200 mg a day is the maximum amount of vitamin C that human cells can absorb, making higher doses a waste. The second study came from the Linus Pauling Institute (Pauling himself took 18,000 mg of vitamin C per day) and was published in the June 1999 issue of the American Journal of Clinical Nutrition. It identified a similar dose, 120 to 200 mg, as the optimal amount for reducing the risk of cardiovascular disease, cancer, cataracts and other chronic conditions.

I wouldn't worry if you've been taking higher doses. Vitamin C is water soluble and anything not used by the body quickly passes out. In fact, I still recommend higher dosages - up to 1,000 mg a day if you are coming down with a cold.

The rest of my antioxidant recommendations are as follows:
Vitamin E: 400 IUs of mixed natural tocopherols (or 80 mg of mixed tocopherols and tocotrienols) a day. Since vitamin E is fat soluble, it must be taken with food to be absorbed. Also, choose natural forms of vitamin E (d-alpha tocopherol with mixed tocopherols, or better yet, mixed tocopherols and tocotrienols) instead of the synthetic form (dl-alpha-tocopherol).
Selenium: 200 micrograms a day of a yeast-bound form. Selenium is a trace mineral with antioxidant and anticancer properties.

Selenium and vitamin E facilitate each other's absorption, so take them together. Doses of selenium above 400 micrograms a day may not be healthy.

Mixed carotenes: 10, 000 - 15,000 IUs a day of beta carotene with other carotenoids, such as alpha carotene, astaxanthin, and zeaxanthin. Make sure the mix gives you lycopene, the red pigment in tomatoes that helps prevent prostate cancer, and lutein, which protects against cataracts and macular degeneration.
Andrew Weil, MD

Oxygen Therapy

Article Description: Used in Germany for over 30 years to successfully treat cancer, stroke, gangrene, eczema, herpes, hepatitis and now AIDS. By 1992 doctors had killed HIV in 300 patients. "Everyone on this planet needs to be made aware that for several years now I have met and keep meeting people who no longer have AIDS, cancer, and almost any other disease you can think of, due to the continual and correct application of oxygen therapies."---Ed McCabe (1992).
Date of Publication: 4/6/2003

Oxygen Therapy
Used in Germany for over 30 years to successfully treat cancer, stroke, gangrene, eczema, herpes, hepatitis and now AIDS. By 1992 doctors had killed HIV in 300 patients.

"Everyone on this planet needs to be made aware that for several years now I have met and keep meeting people who no longer have AIDS, cancer, and almost any other disease you can think of, due to the continual and correct application of oxygen therapies."---Ed McCabe (1992). Ed McCabe is currently in jail, 1998.

"You wouldn’t believe how many FDA officials or relatives or acquaintances of FDA officials come to see me as patients in Hanover. You wouldn’t believe this, or directors of the AMA, or ACA, or the presidents of orthodox cancer institutes. That’s the fact."---Hans Nieper.

"I called all the major network news bureaus, including Public Radio, and reported ozone AIDS cures coming out of Europe. Not a single reporter or show called back for details. I wrote and sent documentation to all the ‘household word’ TV talk show hosts who make their living acting ‘concerned’ and I tried all the ‘AIDS fund raising spokespeople’, show business celebs, even sending proof of their home addresses, but as of yet not one single phone call or inquiry came back for more."—Ed McCabe.

"There is so much medical evidence to support oxygen therapies that no media dared cover it."—Duncan Rhoads, Nexus Editor on Ed McCabe lecture tour of Australia.
"One of the original AIDS experts recently stated that all he could see as a result of all the millions of dollars being spent on AIDS research was that all of his colleagues are now driving more expensive cars."—McCabe.

"I interviewed 15 people who stated they were cured of cancer by using one of the oxygen therapies…amazingly enough, one of them had pancreatic cancer A man had prostate cancer. Someone else had colon cancer. Dr Otto Warburg won the nobel prize twice for stating that the cause of cancer is a normal cell denied 60% of its oxygen requirements….I asked a big cancer specialist …if he had ever heard of Dr Warburg, and he said no. And this specialist’s title was ‘Head of Fermentation Process Laboratories."---McCabe.

Oct 1991, Jim Caplan at Capmed in Pennsylvania sends all 150 top US AIDS researchers copies of Journal of Hematology report showing ozone, when used as a virucide eliminates HIV. He invites questions or response. Not one response was received from any of these "top" researchers using tax money to "find a cure."

Dr Satori, M.D. has had 149 AIDS patients become healthy, 50 of which zero-converted to negative and became virus free by combining ozone with vitamins, minerals and other supplements. In 1992 he was arrested.

"The FDA won’t spend a dime on ozone research, but they spent over $1 million intimidating, harassing, and persecuting me alone." Dr Jonathen Wright

more info at:
http://www.dreddyclinic.com/integrated_med/ozone-therapy.htm

Tea May Reduce Risk of Ovarian Cancer

Tea May Reduce Risk of Ovarian Cancer
Attention tea drinkers, a recent study suggests that women who consume two or more cups of tea daily, over time, may reduce their risk of ovarian cancer.

Researchers from the National Institute of Environmental Medicine in Stockholm, Sweden studied the association between tea consumption and ovarian cancer in some 61,000 women ages 40-76.

They observed a 46 percent lower risk of ovarian cancer in those who consumed two or more cups per day compared to non-drinkers. Additionally, they found an 18 percent lower risk for each additional cup consumed each day.I've posted several other articles touting the potential benefits of tea.

Green tea, for example, may reduce the risk of prostate cancer and green tea extract might aid in fighting bladder cancer.While tea can be a beneficial, it is important to consume in moderation. Previous research has found high levels of fluoride, a toxic substance that can have an adverse effect on your body.

If you drink a lot of tea, look for a low-fluoride brand.Because, when it comes to cancer, prevention is always the best "cure," I urge you to review my major recommendations that can virtually eliminate your cancer risks.
Yahoo News December 13, 2005
Archives of Internal Medicine, Vol. 165, No. 22, December 2005: 1212-1226